Global Alpha Emitters Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Radionuclide Type;

Terbium (Tb-149), Bismuth (Bi-212), Actinium (Ac-225), Radium (Ra-223), Lead (Pb-212), Bismuth (Bi -213), and Others

By Application;

Glioma, Melanoma, Pancreatic Cancer, Ovarian Cancer, Thyroid Cancer, Bone Cancer, Blood Cancer, Endocrine Tumor, and Others

By End User;

Hospitals, Medical Research Institutions, and Others

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn102407880 Published Date: May, 2025 Updated Date: June, 2025

Alpha Emitters Market Overview

Alpha Emitters Market (USD Million)

Alpha Emitters Market was valued at USD 1,697.48 million in the year 2024. The size of this market is expected to increase to USD 14,162.31 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 35.4%.


Global Alpha Emitters Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 35.4 %


Study Period2025 - 2031
Base Year2024
CAGR (%)35.4 %
Market Size (2024)USD 1,697.48 Million
Market Size (2031)USD 14,162.31 Million
Market ConcentrationLow
Report Pages306
1,697.48
2024
14,162.31
2031

Major Players

  • Bayer AG
  • Novartis International AG
  • GE Healthcare
  • Algeta ASA
  • Actinium Pharmaceuticals, Inc
  • Advanced Accelerator Applications
  • Oak Ridge National Laboratory
  • Eckert & Ziegler
  • Curium Pharma
  • Isotopia Molecular Imaging Ltd

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Alpha Emitters Market

Fragmented - Highly competitive market without dominant players


The alpha emitters market is rapidly expanding due to increased use in targeted cancer therapies. These emitters offer highly focused energy delivery that destroys cancer cells with minimal impact on healthy tissues. This has made them a preferred option for treating difficult-to-manage cancers, contributing to their rising demand in radiopharmaceutical applications.

Clinical Applications in Oncology
The utilization of alpha emitters in oncology treatments is growing, with around 45% of the demand driven by therapies for prostate and bone cancers. These emitters show particular promise in targeting resistant tumor cells and addressing minimal residual disease, making them crucial in modern oncology care models.

Technological Progress and Production Innovation
Progress in radioisotope production is propelling market growth. Improved accelerator and generator technologies have enhanced production efficiency and made isotopes more accessible. As a result, nearly 38% of newly developed radiopharmaceuticals now include alpha-emitting isotopes, indicating strong momentum toward next-generation treatments.

Collaborative Developments Across the Industry
Collaborations between biotech companies and nuclear medicine developers are shaping the alpha emitters market. More than 50% of alpha-based therapies under development are part of such partnerships. These collaborations help accelerate research, improve supply logistics, and streamline pathways for clinical adoption.

Research Support and Regulatory Advances
Growing regulatory support and investment in oncological research are amplifying development efforts. Favorable conditions, such as funding incentives and streamlined approval processes, are encouraging innovation. This supportive landscape is expected to fuel continuous growth and diversification of alpha emitter applications in cancer care.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Radionuclide Type
    2. Market Snapshot, By Application
    3. Market Snapshot, By End User
    4. Market Snapshot, By Region
  4. Alpha Emitters Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing adoption of alpha emitters in cancer therapy
        2. Technological advancements in nuclear medicine
        3. Rising awareness about radiation therapy
        4. Favorable regulatory environment
      2. Restraints
        1. High cost of alpha emitter-based therapies
        2. Limited availability of alpha emitter isotopes
        3. Concerns regarding radiation safety
        4. Competition from alternative therapies
      3. Opportunities
        1. Expanding applications in precision medicine
        2. Emerging markets in Asia-Pacific and Latin America
        3. Collaborations and partnerships
        4. Investment in novel production technologies
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Alpha Emitters Market, By Radionuclide Type, 2021 - 2031 (USD Million)
      1. Terbium (Tb-149)
      2. Bismuth (Bi-212)
      3. Actinium (Ac-225)
      4. Radium (Ra-223)
      5. Lead (Pb-212)
      6. Bismuth (Bi -213)
      7. Others
    2. Alpha Emitters Market, By Application, 2021 - 2031 (USD Million)
      1. Glioma
      2. Melanoma
      3. Pancreatic Cancer
      4. Ovarian Cancer
      5. Thyroid Cancer
      6. Bone Cancer
      7. Blood Cancer
      8. Endocrine Tumor
      9. Others
    3. Alpha Emitters Market, By End User, 2021 - 2031 (USD Million)
      1. Hospitals
      2. Medical Research Institutions
      3. Others
    4. Alpha Emitters Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Bayer AG
      2. Novartis International AG
      3. GE Healthcare
      4. Algeta ASA
      5. Actinium Pharmaceuticals, Inc
      6. Advanced Accelerator Applications
      7. Oak Ridge National Laboratory
      8. Eckert & Ziegler
      9. Curium Pharma
      10. Isotopia Molecular Imaging Ltd
  7. Analyst Views
  8. Future Outlook of the Market